Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.
NCT ID: NCT00212355
Last Updated: 2025-03-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
37 participants
INTERVENTIONAL
2005-03-31
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Zinc Acetate to Treat Wilson's Disease in Japan.
NCT00212368
Study of Zinc for Wilson Disease
NCT00004338
A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease
NCT03659331
The Individual Therapy for Patients With Wilson's Disease
NCT03957720
Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan
NCT01229579
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NPC-02
zinc acetate
NPC-02
zinc acetate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NPC-02
zinc acetate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Malignant tumor
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nobelpharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Koudou Ishii, M.D.
Role: STUDY_DIRECTOR
National MINAMIYOKOHAMA Hospital
References
Explore related publications, articles, or registry entries linked to this study.
Shimizu N, Fujiwara J, Ohnishi S, Sato M, Kodama H, Kohsaka T, Inui A, Fujisawa T, Tamai H, Ida S, Itoh S, Ito M, Horiike N, Harada M, Yoshino M, Aoki T. Effects of long-term zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism. Transl Res. 2010 Dec;156(6):350-7. doi: 10.1016/j.trsl.2010.08.007. Epub 2010 Sep 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NPC-02-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.